Navigating renal safety in the biologic treatment of psoriasis: from immunologic mechanisms to clinical practice - Takeaways - MDSpire

Navigating renal safety in the biologic treatment of psoriasis: from immunologic mechanisms to clinical practice

  • By

  • Zijie Tang

  • Jintong Wu

  • Meihan Dong

  • Chengxin Li

  • Rui Wang

  • May 1, 2026

  • 0 min

Share

  • 1

    Psoriasis is a chronic inflammatory disorder linked to systemic diseases, including chronic kidney disease (CKD) and end-stage renal disease (ESRD).

  • 2

    Biologic therapies targeting inflammatory cytokines have transformed psoriasis treatment but raise concerns about their renal safety and potential nephrotoxicity.

  • 3

    Clinical studies suggest biologic therapy does not increase CKD incidence compared to conventional treatments like methotrexate.

  • 4

    Understanding the mechanisms linking psoriasis and kidney injury is crucial for optimizing biologic therapies to protect renal function.

  • 5

    A multidisciplinary approach is essential for managing psoriasis patients with renal concerns, balancing treatment efficacy and minimizing nephrological risks.

Original Source(s)

Navigating renal safety in the biologic treatment of psoriasis: from immunologic mechanisms to clinical practice

  • by Zijie Tang, Jintong Wu, Meihan Dong, Chengxin Li, Rui Wang

  • May 1, 2026

Related Content

Summary of Research: Apremilast Improves Skin Outcomes in Pediatric Plaque Psoriasis of Shorter Disease Duration: 52-Week Results from the SPROUT Phase 3 Trial

The Role of Inflammatory Biomarkers in Disease Severity and Treatment Response across Psoriasis, Atopic Dermatitis, and Hidradenitis Suppurativa—A Narrative Review

Investigating the Therapeutic Mechanisms and Key Bioactive Compounds of Solanum nigrum in Treating Psoriatic Lesions